This approval comes after detailed examination of the regulatory submission by the regulatory authorities of the Republic of Korea. Cellestis will market the test in the Republic of Korea via its distributor, Woongbee MeDiTech Inc., who has been instrumental in obtaining the regulatory approval.
The prevalence of tuberculosis in the Republic of Korea has been reported as 135 per 100,000 pop/yr and BCG vaccination is mandatory. South Korean researchers have shown a keen interest in QFT and have utilised the test in clinical trials in different TB testing populations, such as health care workers and the military.
"We are pleased by this approval and the availability of QFT in South Korea expands the Asian market." said Dr Tony Radford, CEO of Cellestis. "We are very grateful for the assistance provided by Woongbee MeDiTech Inc, in navigating the intricacies of the regulatory process and look forward to working with them to develop and grow the market. The regulatory approval involved detailed analysis of the clinical performance and quality compliance of our test, and is another official ratification of QFT. South Korea now joins the growing list of countries that have approved QFT."
Details on Woongbee MeDiTech Inc. may be found on:
and within South Korea they may be contacted on 031 776 330